<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548353" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548353/" /><meta name="ncbi_pagename" content="Doxycycline - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Doxycycline - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Doxycycline" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2019/01/23" /><meta name="citation_pmid" content="31643675" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548353/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Doxycycline" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2019/01/23" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548353/" /><meta name="description" content="Doxycycline is a semisynthetic, tetracycline related bacteriostatic antibiotic that has been linked to rare instances of acute cholestatic liver injury." /><meta name="og:title" content="Doxycycline" /><meta name="og:type" content="book" /><meta name="og:description" content="Doxycycline is a semisynthetic, tetracycline related bacteriostatic antibiotic that has been linked to rare instances of acute cholestatic liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548353/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Doxycycline/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548353/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D2275046647910000000005FD01B4.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548353_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548353_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/DoxorubicinEpirubici/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Doxylamine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548353_"><span class="title" itemprop="name">Doxycycline</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 23, 2019</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Doxycycline.OVERVIEW"><h2 id="_Doxycycline_OVERVIEW_">OVERVIEW</h2><div id="Doxycycline.Introduction"><h3>Introduction</h3><p>Doxycycline is a semisynthetic, tetracycline related bacteriostatic antibiotic that has been linked to rare instances of acute cholestatic liver injury.</p></div><div id="Doxycycline.Background"><h3>Background</h3><p>Doxycycline (dox" i sye' kleen) is a semisynthetic tetracycline that is used for mild-to-moderate infections due to susceptible organisms. Doxycycline, like other tetracyclines, is active against a wide spectrum of gram-positive and gram-negative bacteria as well as against several rickettsia, spirochetes, chlamydia and mycoplasma. Unlike tetracycline and oxytetracycline, doxycycline has excellent oral availability and wide tissue penetration. Indications include upper respiratory, skin, or soft tissue infections due to susceptible bacteria, gonorrhea and syphilis in penicillin-allergic patients, non-gonococcal urethritis, acute pelvic inflammatory disease, epididymitis, oorchitis, Lyme disease, and as prophylaxis against traveler&#x02019;s diarrhea. Doxycycline is also used chronically as treatment of acne. Doxycycline was approved for use in the United States in 1967 and is still widely used, with more than 11 million prescriptions filled yearly. Doxycycline is available in multiple generic forms in capsules and tablets ranging from 20 to 100 mg, and as oral suspensions for pediatric use. Typical adult doses are 100 to 200 mg twice daily for 7 to 30 days. Parenteral forms for intravenous or intramuscular administration are also available. Trade names for doxycycline include Vibramycin, Oracea, Adoxa, Monodox and Doxycin. Common side effects include headache, dizziness, nausea, gastrointestinal upset, skin and tooth discoloration and rash.</p></div><div id="Doxycycline.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Doxycycline has been associated with rare instances of hepatic injury, generally arising within 1 to 2 weeks of starting therapy, sometimes with a history of previous administration of the agent without injury. The pattern of injury ranges from hepatocellular to cholestatic and is probably most commonly mixed. The onset is often abrupt and can be accompanied by signs of hypersensitivity, such as fever, rash and eosinophilia (DRESS syndrome). Recovery is usually rapid and usually complete within 4 to 6 weeks. However, instances of severe and prolonged cholestatic liver injury have been reported with oral doxycycline. The autoimmune-like hepatitis that has been described with minocycline has not been linked to doxycycline, despite similarities in chemical structure and similar indications and uses, perhaps because it is used less frequency in a low dose, long term regimen. High dose intravenous doxycycline can cause acute fatty liver typical of that caused by intravenous tetracycline, particularly in susceptible patients such as pregnant women. This type of injury is, however, quite rare. Nevertheless, for these reasons, the duration and dose of parenteral doxycycline therapy should be minimized.</p><p>Likelihood score: B (highly likely but rare cause of clinically apparent liver injury).</p></div><div id="Doxycycline.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the idiosyncratic liver injury associated with doxycycline is unknown, but several features (short latency, recurrence with reexposure) suggest an immunoallergic etiology. The injury is similar to what has been described much more frequency with minocycline which has been linked to HLA-B*35:01, although only in a minority of cases.</p></div><div id="Doxycycline.Outcome_and_Management"><h3>Outcome and Management</h3><p>Recovery after withdrawal of doxycycline is usually rapid, but in instances with severe cholestasis, can require 2 to 6 months. No case of acute liver failure has been reported due to doxycycline, but rare instances of vanishing bile duct syndrome have been linked to its use. Cross sensitivity to hepatic injury between minocycline and doxycycline has not been shown, but both can cause a short incubation period acute hepatitis with immunoallergic features, so that some degree of cross reactivity may occur.</p><p>Drug Class: <a href="/books/n/livertox/Antiinfective/">Antiinfective Agents</a>, <a href="/books/n/livertox/Tetracyclines/">Tetracyclines</a></p></div></div><div id="Doxycycline.CASE_REPORT"><h2 id="_Doxycycline_CASE_REPORT_">CASE REPORT</h2><div id="Doxycycline.Case_1._Cholestatic_hepatiti"><h3>Case 1. Cholestatic hepatitis attributed to doxycycline therapy.</h3><p>[Modified from: Bj&#x000f6;rnsson E, Lindberg J, Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol 1997; 32: 390-5.]</p><p>A 32 year old man with fever and cough was treated with doxycycline for suspected pneumonitis and developed skin rash, abdominal pain and dark urine one day later. Symptoms of fatigue, nausea and pruritus arose and doxycycline was stopped after 8 days of therapy. His serum enzymes were elevated and he was mildly jaundiced with a total bilirubin of 4.4 mg/dL (Table). He also had eosinophilia (13.5%). He tested negative for antibodies to hepatitis A, B, and C as well as markers of acute CMV and Epstein Barr infection. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.autoantibodies/">Autoantibodies</a> were negative, and an abdominal ultrasound was normal. He remained jaundiced for several months and underwent a liver biopsy that showed intrahepatic cholestasis with mild inflammatory changes suggestive of drug induced liver injury. In follow-up at 3 and again at 18 months, all liver tests had returned to normal.</p><div id="Doxycycline.Key_Points"><h4>Key Points</h4><div id="Doxycycline.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548353/table/Doxycycline.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Doxycycline.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Doxycycline.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Doxycycline (200 mg once daily for 8 days)</td></tr></thead><tbody><tr><th headers="hd_h_Doxycycline.T1_1_1_1_1" id="hd_b_Doxycycline.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Doxycycline.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Mixed (R=3.9), later hepatocellular (R=10)</td></tr><tr><th headers="hd_h_Doxycycline.T1_1_1_1_1" id="hd_b_Doxycycline.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Doxycycline.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">3+ (jaundice and hospitalization)</td></tr><tr><th headers="hd_h_Doxycycline.T1_1_1_1_1" id="hd_b_Doxycycline.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Doxycycline.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">1 day to symptoms, 8 days to jaundice</td></tr><tr><th headers="hd_h_Doxycycline.T1_1_1_1_1" id="hd_b_Doxycycline.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Doxycycline.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">3 months</td></tr><tr><th headers="hd_h_Doxycycline.T1_1_1_1_1" id="hd_b_Doxycycline.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Doxycycline.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">None mentioned</td></tr></tbody></table></div></div></div><div id="Doxycycline.Laboratory_Values"><h4>Laboratory Values</h4><div id="Doxycycline.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548353/table/Doxycycline.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Doxycycline.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a>* (U/L)</th><th id="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P* (U/L)</th><th id="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>* (mg/dL)</th><th id="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1 hd_h_Doxycycline.T2_1_1_1_2 hd_h_Doxycycline.T2_1_1_1_3 hd_h_Doxycycline.T2_1_1_1_4 hd_h_Doxycycline.T2_1_1_1_5 hd_h_Doxycycline.T2_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Doxycycline given for 8 days for suspected pneumonia</td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">1 day</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">NA</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">NA</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">NA</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Rash and nausea</td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">173</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">130</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.4</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Doxycycline stopped</td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">11 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">194</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">112</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">5.0</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Negative viral markers</td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">36 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">28 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">431</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">104</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">8.1</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">53 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">45 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">442</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">91</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">7.1</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">56 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">48 days</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">474</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">104</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">7.2</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">2 months</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 months</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">743</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">100</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.6</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">3 months</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 months</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">388</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">87</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">3.1</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 months</td><td headers="hd_h_Doxycycline.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 months</td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">32</td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">61</td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.8</td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Doxycycline.T2_1_1_1_1 hd_h_Doxycycline.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Doxycycline.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Doxycycline.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;115</b></td><td headers="hd_h_Doxycycline.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Doxycycline.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>* Estimated from Figure 1 and converted from &#x000b5;kat/l and &#x000b5;mol/L.</p></div><div id="Doxycycline.Comment"><h4>Comment</h4><p>A convincing history, presentation, biochemical pattern and course for drug induced liver disease with a rapid onset, mixed followed by hepatocellular pattern of enzyme elevations and fairly prolonged jaundice. The only medication taken was doxycycline, which the patient had received at least twice in the past. The short latency to onset suggests previous sensitization. Recovery was slow but complete. Thus, the overall presentation is quite convincing as immunoallergic drug induced liver injury due to doxycycline. Future exposures to doxycycline as well as other tetracyclines should be avoided.</p></div></div></div><div id="Doxycycline.PRODUCT_INFORMATION"><h2 id="_Doxycycline_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Doxycycline.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Doxycycline &#x02013; Generic, Monodox&#x000ae;, Vibramycin&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiinfective Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=doxycycline" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Doxycycline.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Doxycycline_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Doxycycline.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548353/table/Doxycycline.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Doxycycline.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Doxycycline.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Doxycycline.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Doxycycline.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Doxycycline.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Doxycycline.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Doxycycline Monohydrate</td><td headers="hd_h_Doxycycline.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135017344%20135017344" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">17086-28-1</a></td><td headers="hd_h_Doxycycline.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C22-H24-N2-O8.H2-O</td><td headers="hd_h_Doxycycline.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548353/bin/_17086-28-1.jpg" alt="2D chemical structure of 17086-28-1" /></div></td></tr></tbody></table></div></div></div><div id="Doxycycline.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Doxycycline_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 23 January 2019</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Doxycycline.R1">Zimmerman HJ. Tetracyclines. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999. p. 599-602.<div><i>(Expert review of tetracycline and liver injury published in 1999; the tetracyclines cause two forms of drug induced liver injury, microvesicular fat and liver failure occurring after 4-10 days with high does of parenteral tetracyclines and an idiosyncratic liver injury that occurs with the oral agents, doxycycline causing a cholestatic and minocycline a hepatocellular injury which may be associated with autoimmune features).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R2">Moseley RH. Tetracyclines. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, p. 468.<div><i>(Expert review of tetracycline induced liver injury mentions that the hepatotoxicity of intravenous tetracycline is of historic interest only as it is no longer given parenterally; both doxycycline and minocycline have been associated with idiosyncratic liver injury).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R3">MacDougall C, Chambers HF. Tetracyclines and glycylcyclines. Protein synthesis inhibitors and miscellaneous antibacterial agents. In, Brunton LL, Chabner KA, Knollman KC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1521-6.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R4">Wruble LD, Ladman AJ, Britt LG, Cummins AJ. Hepatotoxicity produced by tetracycline overdosage. JAMA 1965; 192: 6-8.  [<a href="/pubmed/14262279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14262279</span></a>]<div><i>(56 year old woman with cecal volulus developed jaundice [bilirubin 7.8 mg/dL, AST 98 U/L, Alk P normal] 2 days after receiving 8 g of tetracycline, subsequently progressing to liver failure and death; autopsy showed fatty liver).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R5">Tetracyclines and the liver in pregnancy. Lancet 1966; 1: 357-8.  [<a href="/pubmed/4159865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4159865</span></a>]<div><i>(Editorial on the history of acute fatty liver of pregnancy, first described by Sheehan in 1940 and later linked to high dose iv tetracycline in pregnancy, but also in nonpregnant women and in men).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R6">Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 1981; 26: 135-41.  [<a href="/pubmed/7230149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7230149</span></a>]<div><i>(Two cases of acute fatty liver over a 15 year period and 60,000 deliveries; one woman received tetracycline for 3 days, the second had no history of its use, but had tetracycline detected in bony tissue suggestive of chronic use).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R7">B&#x000f6;cker R, Estler CJ, M&#x000fc;ller S, Pfandzelter C, Spachm&#x000fc;ller B. Comparative evaluation of the effects of tetracycline, rolitetracycline and doxycycline on some blood parameters related to liver function. Arzneimittelforschung 1982; 32: 237-41.  [<a href="/pubmed/7200783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7200783</span></a>]<div><i>(Minocycline caused a dose dependent rise in AST and increase in triglycerides, but no hepatic histological changes in mice; similar findings were previously reported with tetracycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R8">Schrumpf E, Nordgard K. Unusual cholestatic hepatotoxicity of doxycycline in a young male? Scand J Gastroenterol 1986; 21 (Suppl 120): 68. Not in PubMed.<div><i>(Abstract: Patient developed severe and prolonged cholestatic hepatitis after 2 weeks of oral doxycycline [bilirubin 9.8 rising to 69.5 mg/L, ALT 53 to 132 U/L, Alk P 283 to 775 U/L] and severe itching; ultimate recovery after 6 months).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R9">Lienart F, Morissens M, Jacobs P, Ducobu J. Doxycycline and hepatotoxicity. Acta Clin Belg 1992; 47: 205-8.  [<a href="/pubmed/1332350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1332350</span></a>]<div><i>(42 year old woman with severe cardiomyopathy developed encephalopathy and enzyme elevations with jaundice after 5 days of oral doxycycline [bilirubin 1.2 mg/dL, ALT 139 U/L, Alk P 373 U/L, ammonia 99 mcg/dL], resolving rapidly on stopping; likely due to heart failure and ischemia rather than drug induced liver injury).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R10">Carson JL, Strom BL, Duff A, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993; 119 (7 Pt 1): 576-83.  [<a href="/pubmed/8363168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8363168</span></a>]<div><i>(Case control study using Medicaid billing results between 1980-87 found 107 cases of hospitalization for unexplained hepatitis, odds ratios for erythromycin 5.2; sulfonamides 11.4; tetracyclines 5.2; total of 5 cases exposed to tetracycline, doxycycline or minocycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R11">Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994; 107: 1844-7.  [<a href="/pubmed/7958700" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7958700</span></a>]<div><i>(Two cases of severe and prolonged cholestatic hepatitis and bile duct paucity after oral tetracyclines; 37 year old woman developed jaundice 2 days after 3 day course of doxycycline with prolonged cholestasis [peak bilirubin 30 mg/dL], but ultimate recovery; 63 year old woman developed jaundice 6 weeks after a 2 week course of tetracycline [bilirubin 11.8 mg/dL, ALT 245 U/L], with prolonged jaundice [peak bilirubin 29.5 mg/dL) and persistence of enzyme elevations for &#x0003e;3 years [Alk P 631 U/L, ALT 97 U/L]).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R12">Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-8.  [<a href="/pubmed/1506809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1506809</span></a>]<div><i>(Adverse drug reaction reports between 1978 and 1987 in Denmark; no tetracycline is mentioned as a cause).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R13">Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years&#x02019; experience. N Z Med J 1996; 109: 315-9.  [<a href="/pubmed/8816722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8816722</span></a>]<div><i>(Adverse drug reaction reports identified 943 liver injuries over 21 years in New Zealand; triacetyloleandomycin accounted for 21 cases [2.1%] and minocycline for at least 4).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R14">Tham SN, Kwok YK, Chan HL. Cross-reactivity in fixed drug eruptions to tetracyclines. Arch Dermatol 1996; 132: 1134-5.  [<a href="/pubmed/8795565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8795565</span></a>]<div><i>(Among 9 Chinese patients with a fixed drug eruption due to tetracycline, all had recurrence on doxycycline and 3 on minocycline; no mention of liver involvement).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R15">Bj&#x000f6;rnsson E, Lindberg J, Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol 1997; 32: 390-5. Review.  [<a href="/pubmed/9140164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9140164</span></a>]<div><i>(32 year old man developed abdominal pain, dark urine and rash within 24 hours of starting doxycycline which he had received in the past [bilirubin 4.3- 8.1 mg/dL, ALT 3.5 times ULN, Alk P 1.1 times ULN], resolving within 3 months of stopping; thorough review of all published and SADRAC reported cases of oral tetracycline associated liver injury found 15 cases, only 6 rated as likely, none with tetracycline, 5 doxycycline, 1 lymecycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R16">Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133: 1224-30.  [<a href="/pubmed/9382560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9382560</span></a>]<div><i>(Review of toxicity of tetracyclines from literature and a Canadian database; minocycline had the highest rates of adverse events, but all were relatively safe: no lupus-like syndrome associated with doxycycline or tetracycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R17">Westermann GW, B&#x000f6;hm M, Bonsmann G, Rahn KH, Kisters K. Chronic intoxication by doxycycline use for more than 12 years. J Intern Med 1999; 246: 591-2.  [<a href="/pubmed/10620103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10620103</span></a>]<div><i> (38 year old man took large doses of doxycycline chronically and developed repeated bouts of mild jaundice [bilirubin 3.4-5.0 mg/dL, ALT 44-118 U/L, Alk P 466 U/L] and weakness, skin discoloration and heart block, resolving upon stopping).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R18">Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159: 493-7.  [<a href="/pubmed/10074958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10074958</span></a>]<div><i>(Case control study in 27,688 acne patients in UK database, risk of lupus increased 8.5 fold in minocycline treated patients, not with other tetracyclines, typically long term therapy; liver involvement not mentioned; more common in women, absolute risk low).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R19">Firouzmand M, Zafrani ES, Dhumeaux D, Mallat A. [Microvesicular steatosis after administration of therapeutic doses of doxycycline] Gastroenterol Clin Biol 2002; 26: 1176-7. French.  [<a href="/pubmed/12520208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12520208</span></a>]<div><i>(65 year old woman with alcoholic liver disease developed jaundice and mild increases in ALT and Alk P when given 1 month course of doxycycline; liver biopsy showed fat, much was microvesicular, but patient was also on ofloxacillin, rifampin and recently received ampicillin and gentamicin for osteomyelitis).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R20">Selimoglu MA, Ertekin V. Autoimmune hepatitis triggered by Brucella infection or doxycycline or both. Int J Clin Pract 2003; 57: 639-41.  [<a href="/pubmed/14529072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14529072</span></a>]<div><i>(11 year old girl was found to have abnormal liver tests 3 weeks after finishing a 6 week course of doxycycline for acute brucellosis [bilirubin 1.2 mg/dL, ALT 222 U/L, Alk P 561 U/L, ANA negative, HLA B8 DRB1*03], a liver biopsy showing inflammation, necrosis and bridging fibrosis, improving on prednisone therapy, relapsing on stopping and ultimately requiring long term azathioprine therapy).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R21">Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23.  [<a href="/pubmed/15390328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15390328</span></a>]<div><i>(Among ~50,000 liver transplants done in the US between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, none of which were attributed to minocycline, doxycycline or tetracycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R22">Bj&#x000f6;rnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-1101.  [<a href="/pubmed/16165719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16165719</span></a>]<div><i>(Among 103 cases of fulminant drug induced liver injury reported to a Swedish registry between 1966 and 2002, one case was attributed to doxycycline, but no other tetracycline mentioned).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R23">Andrade RJ, Lucena MI, Fern&#x000e1;ndez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005; 129: 512-21.  [<a href="/pubmed/16083708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16083708</span></a>]<div><i>(Reports to a Spanish network found 461 cases of drug induced liver disease; no tetracycline was listed among the top 20 agents implicated [at least 5 cases]).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R24">Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27: 1329-42.  [<a href="/pubmed/16291409" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16291409</span></a>]<div><i>(Systematic review of overall safety of doxycycline and minocycline stressing overall low rate of adverse events [13-72 per million prescriptions]; little mention of liver toxicity).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R25">Bj&#x000f6;rnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006; 38: 33-8.  [<a href="/pubmed/16054882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16054882</span></a>]<div><i>(Survey of drug induced liver fatalities reported to WHO database between 1968-2003 revealed 4690 reports &#x02013; 89% from the US; the list of most 21 most commonly implicated drugs did not include a tetracycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R26">Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007; 157: 540-6.  [<a href="/pubmed/17596147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17596147</span></a>]<div><i>(Analysis of UK database on 97,694 subjects with acne, 25% received minocycline, 16% doxycycline and 45% other tetracyclines. Hazard ratio for lupus-like syndrome was 3.11 for minocycline; no increased risk or association with doxycycline or other tetracyclines).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R27">Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 2007; 32: 483-7.  [<a href="/pubmed/17875115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17875115</span></a>]<div><i>(Analysis of 2 years of Medicaid claims in California found 3377 cases of &#x0201c;hepatotoxicity&#x0201d;; 20 had received tetracycline &#x0003c;45 days before onset; only 4 controls had: adjusted odds ratio 3.7; not elevated for doxycycline; this despite safety record of oral tetracyclines and known hepatotoxicity of doxycycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R28">Hempel U, Sch&#x000e4;ffler A, Salzberger B, R&#x000fc;mmele P, Sch&#x000f6;lmerich J. [A 42-year-old farmer with nonspecific leukocytosis and elevated transaminases. Acute septic reaction in Coxiella burnetii infection.] Internist (Berl) 2008; 49: 743-6. German.  [<a href="/pubmed/18309471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18309471</span></a>]</div></li><li><div class="bk_ref" id="Doxycycline.R29">Meropol SB, Chan KA, Chen Z, Finkelstein JA, Hennessy S, Lautenbach E, Platt R, et al. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf 2008 17: 423-32.  [<a href="/pmc/articles/PMC4269235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4269235</span></a>] [<a href="/pubmed/18215001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18215001</span></a>]<div><i>(Analysis of 3 large UK and US databases on medication use and clinical outcomes covering ~6 million patients for adverse events related to &#x0003e;1 month of either amoxicillin [0-1.2/100,000], ciprofloxacin [0-5.7/100,000] and doxycycline [0-0.9/100,000 person days], but no mention of liver toxicities).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R30">Carrascosa MF, Lucena MI, Andrade RJ, Caviedes JRS, et al. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clin Ther 2009; 31: 1014-19.  [<a href="/pubmed/19539102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19539102</span></a>]<div><i>(63 year old man developed acute liver injury 1 week after starting a 3 day course of levofloxacin and 5 days after starting doxycycline [bilirubin 4.0 rising to &#x0003e;35 mg/dL, ALT 1577 U/L, Alk P 189 U/L], with subsequent progressive liver failure and death; biopsy showed massive necrosis).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R31">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i> (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, minocycline accounted for 3 cases, doxycycline for 3 cases and tetracycline was listed as a secondary possible cause for one).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R32">Chavant F, Lafay-Chebassier C, Beauchant M, Perault-Pochat MC. [Doxycycline induced hepatitis]. Gastroenterol Clin Biol 2008; 32: 825-7. French.  [<a href="/pubmed/18823729" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18823729</span></a>]<div><i>(37 year old man developed fatigue 6 weeks after starting doxycycline [bilirubin 2.8 mg/dL, ALT 2322 U/L, Alk P 184 U/L, ANA 1:100], resolving within 6 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R33">Robles DT, Leonard JL, Compton N, Waghmare A, McDonough KA, George E, Wolgamot G, Fleckman P. Severe drug hypersensitivity reaction in a young woman treated with doxycycline. Dermatology 2008; 217: 23-6.  [<a href="/pubmed/18332631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18332631</span></a>]<div><i>(20 year old woman developed severe rash and fever 3 weeks after starting doxycycline for acne [bilirubin 2.5 mg/dL, ALT 133 U/L, Alk P 205 U/L, eosinophils 980/&#x000b5;L], requiring intubation and corticosteroid therapy and 3 week hospitalization, ultimately resolving).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R34">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-8.  [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database containing 9036 hepatic adverse drug reactions in children includes 117 cases attributed to minocycline, but no other tetracycline listed in the top 40 causes).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R35">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-404.  [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(313 cases of drug induced liver injury were seen over a 12 year period at a large hospital in Bangalore, India; none were due to tetracyclines).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R36">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury and 25 to antituberculosis agents, including 15 to isoniazid alone [ranking first], 6 to isoniazid combined with other agents, 3 to rifampin and pyrazinamide, and 1 to dapsone).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R37">Bj&#x000f6;rnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-8.  [<a href="/pubmed/20512992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20512992</span></a>]<div><i>(Among 261 cases of autoimmune hepatitis seen at the Mayo Clinic between 1997 and 2007, 24 were attributed to drugs, 11 to minocylcine, 11 to nitrofurantoin and 2 to others; all responded to corticosteroid therapy and all who were withdrawn did not relapse).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R38">Mailhol C, Tremeau-Martinage C, Paul C, Godel A, Lamant L, Giordano-Labadie F. [Severe drug hypersensitivity reaction (DRESS syndrome) to doxycycline]. Ann Dermatol Venereol 2010; 137: 40-3. French.  [<a href="/pubmed/20110067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20110067</span></a>]<div><i>(59 year old woman developed fever, rash and facial edema 3 weeks after starting doxycycline for malaria prophylaxis [bilirubin normal, ALT 278 U/L, eosinophils 15%, atypical lymphocytosis], resolving on discontinuation).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R39">Leitner JM, Graninger W, Thalhammer F. Hepatotoxicity of antibacterials: Pathomechanisms and clinical. Infection 2010; 38: 3-11.  [<a href="/pubmed/20107858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20107858</span></a>]<div><i>(Review of hepatotoxicity of antibiotics; mentions that hepatotoxicity from oral tetracycline is rare ~1.5 cases per million prescriptions, whereas minocycline has been associated with either an immediate reaction with eosinophilia, dermatitis and enzyme elevations or a delayed autoimmune hepatitis-like syndrome).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R40">Glenn C, Feldman SR. Letter: Tetracycline-induced hepatotoxicity. Dermatol Online J 2011; 17: 14.  [<a href="/pubmed/22233750" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22233750</span></a>]<div><i>(49 year old woman developed fatigue, edema, low albumin and raised alkaline phosphatase levels [bilirubin and ALT normal] 6 months after starting oral tetracycline for rosacea, albumin and alkaline phosphatase levels returning to normal upon stopping, later tolerating doxycycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R41">Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011; 56: 958-76. <em>(Review of drug induced autoimmune hepatitis-like syndromes, most commonly caused by nitrofurantoin and minocycline, but also with hydralazine, methyldopa and more rarely with statins, fibrates, NSAIDs, various herbals and tumor necrosis factor antagonists).</em></div></li><li><div class="bk_ref" id="Doxycycline.R42">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to doxycycline or other tetracyclines).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R43">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, 37 of which were attributed to an antibiotic, but none to a tetracycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R44">Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R, et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol 2015; 79: 988-99.  [<a href="/pmc/articles/PMC4456131/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4456131</span></a>] [<a href="/pubmed/25444550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25444550</span></a>]<div><i> (Among 76 inpatients with hepatitis of uniknown cause enrolled in a prospective case-cohort surveillance study between 2002 and 2011, one was attributed to doxycycline, but no other tetracycline was implicated).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R45">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 323 [36%] were attributed to antibiotics including 28 [3%] to minocycline and 4 [0.4%] to doxycycline).</i></div></div></li><li><div class="bk_ref" id="Doxycycline.R46">Tang DM, Koh C, Twaddell WS, von Rosenvinge EC, Han H. Acute hepatocellular drug-induced liver injury from bupropion and doxycycline. ACG Case Rep J 2015; 3: 66-8. [<a href="/pmc/articles/PMC4612764/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4612764</span></a>] [<a href="/pubmed/26504884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26504884</span></a>]<div><i>(29 year old African American man developed jaundice 14 days after starting bupropion and doxycycline [bilirubin 19.9 mg/dL, ALT 888 U/L, Alk P 234 U/L, INR 3.0, eosinophils 5%] with resolution within 2 months on prednisone, the authors suggesting that bupropion was the most likely cause). </i></div></div></li><li><div class="bk_ref" id="Doxycycline.R47">Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, Aithal GP, et al; Drug-Induced Liver Injury Network (DILIN); Pharmacogenetics of Drug-Induced Liver Injury group (DILIGEN); International Serious Adverse Events Consortium (iSAEC). Minocycline hepatotoxicity: clinical characterization and identification of HLA-B&#x02217;35:02 as a risk factor. J Hepatol 2017; 67: 137-44.  [<a href="/pmc/articles/PMC5634615/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5634615</span></a>] [<a href="/pubmed/28323125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28323125</span></a>]<div><i>(The uncommon HLA allele B*35:02 was found in 4 of 25 [16%] of patients with minocycline hepatotoxicity vs 0.6% in a population control group; those with and without this allele did not different in clinical features or outcome).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548353</span><span class="label">PMID: <a href="/pubmed/31643675" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643675</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/DoxorubicinEpirubici/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Doxylamine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548353&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548353/?report=reader">PubReader</a></li><li><a href="/books/NBK548353/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548353" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548353" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Doxycycline. [Updated 2019 Jan 23].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548353/pdf/Bookshelf_NBK548353.pdf">PDF version of this page</a> (407K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=doxycycline/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Doxycycline: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=doxycycline" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Doxycycline: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4864758" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4864758" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644155" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Demeclocycline</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Demeclocycline<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24978888" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Minocycline and doxycycline, but not tetracycline, mitigate liver and kidney injury after hemorrhagic shock/resuscitation.</a><span class="source">[Shock. 2014]</span><div class="brieflinkpop offscreen_noflow">Minocycline and doxycycline, but not tetracycline, mitigate liver and kidney injury after hemorrhagic shock/resuscitation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kholmukhamedov A, Czerny C, Hu J, Schwartz J, Zhong Z, Lemasters JJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Shock. 2014 Sep; 42(3):256-63. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21771509" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi.</a><span class="source">[Ticks Tick Borne Dis. 2010]</span><div class="brieflinkpop offscreen_noflow">Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ates L, Hanssen-Hübner C, Norris DE, Richter D, Kraiczy P, Hunfeld KP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ticks Tick Borne Dis. 2010 Mar; 1(1):30-4. Epub 2010 Jan 7.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24012766" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Minocycline and doxycycline, but not other tetracycline-derived compounds, protect liver cells from chemical hypoxia and ischemia/reperfusion injury by inhibition of the mitochondrial calcium uniporter.</a><span class="source">[Toxicol Appl Pharmacol. 2013]</span><div class="brieflinkpop offscreen_noflow">Minocycline and doxycycline, but not other tetracycline-derived compounds, protect liver cells from chemical hypoxia and ischemia/reperfusion injury by inhibition of the mitochondrial calcium uniporter.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schwartz J, Holmuhamedov E, Zhang X, Lovelace GL, Smith CD, Lemasters JJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Toxicol Appl Pharmacol. 2013 Nov 15; 273(1):172-9. Epub 2013 Sep 5.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9382560" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Comparative safety of tetracycline, minocycline, and doxycycline.</a><span class="source">[Arch Dermatol. 1997]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Comparative safety of tetracycline, minocycline, and doxycycline.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shapiro LE, Knowles SR, Shear NH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arch Dermatol. 1997 Oct; 133(10):1224-30. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643675" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643675" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:50:43-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D2275046647910000000005FD01B4&amp;ncbi_session=CE8D227504680121_1533SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548353%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548353&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548353/&amp;ncbi_pagename=Doxycycline - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D227504680121_1533SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>